T1	Treatment 139 159	amlodipine camsylate
T2	Treatment 167 186	amlodipine besylate
T3	Treatment 252 271	Amlodipine besylate
T4	Treatment 393 413	Amlodipine camsylate
T5	Treatment 740 760	amlodipine camsylate
T6	Treatment 765 784	amlodipine besylate
T7	Treatment 896 916	amlodipine camsylate
T8	Treatment 931 950	amlodipine besylate
T9	Treatment 1439 1532	randomly assigned to receive oral treatment with amlodipine camsylate or amlodipine besylate.
T10	Treatment 1533 1603	For the first 4 weeks, patients received amlodipine 5 mg QD (morning).
T11	Treatment 1604 1795	After 4 weeks, if either blood pressure was > or =140/ > or =90 mm Hg or SiDBP had not decreased by > or =10 mm Hg from baseline, the dose of amlodipine was increased to 10 mg QD for 4 weeks.
T12	Treatment 1796 2015	Trough blood pressure and heart rate were measured in duplicate with the patient in the sitting position at each clinic visit (baseline [week 0] and weeks 4 and 8 of treatment); mean values were calculated and recorded.
T13	Treatment 2016 2152	At weeks 4 and 8, tolerability was assessed using history taking and laboratory analysis, and compliance was assessed using pill counts.
T14	Treatment 2590 2610	amlodipine camsylate
T15	Treatment 2966 2986	amlodipine camsylate
T16	Treatment 2999 3019	amlodipine besylate)
T17	Treatment 3040 3060	amlodipine camsylate
T18	Treatment 3090 3109	amlodipine besylate
T19	Treatment 3288 3309	(amlodipine camsylate
T20	Treatment 3392 3411	amlodipine besylate
T21	Treatment 3878 3899	(amlodipine camsylate
T22	Treatment 3909 3928	amlodipine besylate
T23	Treatment 4044 4064	amlodipine camsylate
T24	Treatment 4069 4088	amlodipine besylate
T25	Treatment 4154 4174	amlodipine camsylate
T26	Treatment 4222 4241	amlodipine besylate
